Lundbeck reports positive results from head-to-head study of antidepressant
Lundbeck’s antidepressant vortioxetine has reportedly demonstrated advantages compared to Pfizer’s Pristiq, which is only sold in the US.
by andreas lønstrup, translated by daniel pedersen
Pharmaceutical firm Lundbeck’s antidepressant vortioxetine, which is sold under brand names Trintellix and Brintellix, has demonstrated an advantage in a head-to-head study against desvenlafaxine, which Pfizer is marketing in the US as Pristiq, Lundbeck has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck finds new CFO
For subscribers
